Hg-109contemporary Survival Endpoints: An International Diffuse Intrinsic Pontine Glioma Registry Study

Cooney, Tabitha; League-Pascual, James C.; Lane, Adam; Hoffman, Lindsey M.; Bartels, Ute; Bouffet, Éric; Goldman, Stewart; Leary, Sarah; Foreman, Nicholas; Packer, Roger J.; Broniscer, Alberto; Kieran, Mark W.; Minturn, Jane E.; Comito, Melanie; Broxon, Emmett; Shih, Chie‐Schin; Khatua, Soumen; Chintagumpala, Murali; Carret, Anne; Hassall, Tim; Gottardo, Nicholas G.; Baugh, Joshua; Chaney, Brooklyn; Doughman, Renee; Leach, James; Jones, Blaise V.; Fouladi, Maryam; Monje, Michelle; Warren, Kathy

doi:10.1093/neuonc/now073.105

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, although with the development of research, the biological and molecular basis of the occurrence and development of gliomas has been extensively verified, the diagnosis and treatment of tumors have also made significant progress. The prognosis of glioma patients is still poor [ 29 , 30 ]. Therefore, it is necessary further to study the clinical diagnosis and treatment of glioma, explore new risk factors and molecular markers, and develop new therapeutic targets to improve the clinical prognosis of patients with glioma.…”

Section: Discussionmentioning

confidence: 99%

High expression of HOXA4 in patients with glioma indicates unfavorable clinical outcomes

Liu

Lian

et al. 2022

Cell Cycle

View full text Add to dashboard Cite

HOXA4 is a novel oncogene that has been observed in many kinds of tumors, but its role during glioma carcinogenesis and its clinical significance in diagnosing and prognosis human glioma remains unknown. In the present study, the Chinese Glioma Atlas (CGGA)-RNA sequencing database, CGGA microarray, and The Cancer Genome Atlas (TCGA)-RNA seq data from 1674 glioma patients were obtained from online databases and analyzed using quantitative reverse transcription-polymerase chain reaction (RT-qPCR) to detect changes in the expression level of HOXA4 and characterize the relationship between HOXA4 and the clinical characteristics and prognosis of patients with glioma. Gene set enrichment analysis (GSEA) was used to reveal how HOXA4 regulates tumor-related pathways. HOXA4 mRNA levels in glioma tissue were higher than those in adjacent brain tissue. HOXA4 expression was also closely related to the clinical and molecular characteristics of gliomas, such as tumor grade and isocitrate dehydrogenase (IDH) mutation. Functional enrichment analysis revealed that HOXA4 could regulate cancer-related signal pathways, such as Cell cycle, Cell adhesion molecules cams, and JAK/STAT signaling pathway. Results of in vitro experiments confirmed that knockdown of HOXA4 blocks the cell cycle pathway and inhibits the proliferation, invasion and chemotherapy resistance in gliomas. We concluded that HOXA4 was an independent risk factor for glioma and may have clinical diagnostic potential. Meanwhile, our findings revealed that HOXA4 could be used as a biomarker for glioma diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

High expression of HOXA4 in patients with glioma indicates unfavorable clinical outcomes

Liu

Lian

et al. 2022

Cell Cycle

View full text Add to dashboard Cite

show abstract

“…Diffuse intrinsic pontine glioma (DIPG), accounting for about 10% of all brain malignancies, is the deadliest pediatric central nervous system tumor. 1,2 The median progression-free survival (PFS) is 7 months and less than 10% of the patients survive 2 years after diagnosis. 3,4 Magnetic resonance imaging (MRI) is the gold standard for DIPG diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Targeted therapy for pediatric diffuse intrinsic pontine glioma: a single-center experience

et al. 2022

View full text Add to dashboard Cite

Background: Diffuse intrinsic pontine glioma (DIPG) is a fatal disease with a median overall survival (OS) of less than 12 months after diagnosis. Radiotherapy (RT) still remains the mainstay treatment. Several other therapeutic strategies have been attempted in the last years without a significant effect on OS. Although radiological imaging is the gold standard for DIPG diagnosis, the urgent need to improve the survival has led to the reconsideration of biopsy with the aim to better understand the molecular profile of DIPG and support personalized treatment. Methods: In this study, we present a single-center experience in treating DIPG patients at disease progression combining targeted therapies with standard of care. Biopsy was proposed to all patients at diagnosis or disease progression. First-line treatment included RT and nimotuzumab/vinorelbine or temozolomide. Immunohistochemistry-targeted research included study of mTOR/p-mTOR pathway and BRAFv600E. Molecular analyses included polymerase chain reaction, followed by Sanger sequences and/or next-generation sequencing. Results: Based on the molecular profile, targeted therapy was administered in 9 out of 25 patients, while the remaining 16 patients were treated with standard of care. Personalized treatment included inhibition of the PI3K/AKT/mTOR pathway (5/9), PI3K/AKT/mTOR pathway and BRAFv600E (1/9), ACVR1 (2/9) and PDGFRA (1/9); no severe side effects were reported during treatment. Response to treatment was evaluated according to Response Assessment in Pediatric Neuro-Oncology criteria, and the overall response rate within the cohort was 66%. Patients treated with targeted therapies were compared with the control cohort of 16 patients. Clinical and pathological characteristics of the two cohorts were homogeneous. Median OS in the personalized treatment and control cohort was 20.26 and 14.18 months, respectively ( p = 0.032). In our experience, the treatment associated with the best OS was everolimus. Conclusion: Despite the small simple size of our study, our data suggest a prognostic advantage and a safe profile of targeted therapies in DIPG patients, and we strongly advocate to reconsider the role of biopsy for these patients.

show abstract

Hg-109contemporary Survival Endpoints: An International Diffuse Intrinsic Pontine Glioma Registry Study

Cited by 2 publications

References 0 publications

High expression of HOXA4 in patients with glioma indicates unfavorable clinical outcomes

High expression of HOXA4 in patients with glioma indicates unfavorable clinical outcomes

Targeted therapy for pediatric diffuse intrinsic pontine glioma: a single-center experience

Contact Info

Product

Resources

About